Omeros corporation announces availability on its website of materials accompanying presentations of oms906 data at the 2023 european hematology association congress

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 european hematology association (eha) congress in frankfurt, germany are now available on omeros' website. the presentation, which details data from a pre-specified interim analysis from the ongoing phase 1b clinical trial of omeros' lead masp-3 inhibitor oms906 in complement-inhibitor-naÏve adults with paroxysmal nocturnal hemoglobinuria (pnh.
OMER Ratings Summary
OMER Quant Ranking